Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) Gross Margin (2019 - 2025)

Eton Pharmaceuticals' Gross Margin history spans 7 years, with the latest figure at 20.54% for Q3 2025.

  • For Q3 2025, Gross Margin fell 4050.0% year-over-year to 20.54%; the TTM value through Sep 2025 reached 51.36%, up 1539.0%, while the annual FY2024 figure was 60.01%, 655.0% down from the prior year.
  • Gross Margin for Q3 2025 was 20.54% at Eton Pharmaceuticals, down from 63.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 657.4% in Q1 2025 and bottomed at 12.18% in Q4 2023.
  • The 5-year median for Gross Margin is 62.85% (2024), against an average of 94.06%.
  • The largest annual shift saw Gross Margin tumbled -720611bps in 2021 before it soared 59455bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 93.89% in 2021, then dropped by -20bps to 74.84% in 2022, then tumbled by -84bps to 12.18% in 2023, then soared by 356bps to 55.6% in 2024, then plummeted by -63bps to 20.54% in 2025.
  • Per Business Quant, the three most recent readings for ETON's Gross Margin are 20.54% (Q3 2025), 63.0% (Q2 2025), and 657.4% (Q1 2025).